Health knowledge made personal
Join this community!
› Share page:
Go
Search posts:

The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases

Posted Apr 30 2008 5:00pm

Description of Invention:
This application describes a composition and method for treating inflammatory bowel disease or other autoimmune diseases. The composition utilizes a vector which contains a first promoter which controls the expression of a regulatory transcription factor and a second inducible promoter which controls the expression of the gene of interest. The preferred gene of interest encodes an isoform of TGF-beta such as TGF-beta1 or TGF-beta3. The isoform of TGF-beta does not have to be hTGF-beta and can be a latent or active isoform of TGF-beta. The preferred inducible promoter is TRE-CMV which can be induced using doxycycline. The usefulness of the composition for treating autoimmune diseases is demonstrated in the application in a murine model of inflammatory bowel disease in which intestinal inflammation was abrogated by the administration of a plasmid vector encoding active TGF-beta. The composition may be administered by a variety of delivery systems and intranasal delivery is exemplified.

Inventors:
Warren Strober (NIAID)


Patent Status:
HHS, Reference No. E-096-2000/0
US, , Patent No. 7,531,352, Issued 12 May 2009



Portfolios:
Cancer
Cancer - Therapeutics
Gene Based Therapies
Gene Based Therapies - Therapeutics
Internal Medicine
Internal Medicine - Therapeutics



For Additional Information Please Contact:
Patrick McCue Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd. Suite 325,
Rockville, MD 20852
United States
Email: McCuepat@mail.nih.gov
Phone: 301-496-7057
Fax: 301-402-0220


Ref No: 1270

Updated: 05/2008

Post a comment
Write a comment:

Related Searches